Clinical Trials
98
Active:26
Completed:1
Trial Phases
5 Phases
Phase 1:45
Phase 2:30
Phase 3:14
+2 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (97 trials with phase data)• Click on a phase to view related trials
Phase 1
45 (46.4%)Phase 2
30 (30.9%)Phase 3
14 (14.4%)Not Applicable
7 (7.2%)Phase 4
1 (1.0%)A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma and Other Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Head and Neck Squamous Cell CarcinomaSolid Tumor
- Interventions
- First Posted Date
- 2025-11-18
- Last Posted Date
- 2025-11-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 16
- Registration Number
- NCT07232524
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Non Small Cell Lung CancerSolid Tumor
- Interventions
- First Posted Date
- 2025-11-18
- Last Posted Date
- 2025-11-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT07232420
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of Lutetium [177Lu] BL-ARC001 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
Not Applicable
Not yet recruiting
- Conditions
- Gastrointestinal TumorsSolid Tumors
- Interventions
- Drug: Lutetium [177Lu] BL-ARC001
- First Posted Date
- 2025-11-18
- Last Posted Date
- 2025-11-18
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT07232407
- Locations
- 🇨🇳
Sichuan Cancer Hospital, Chengdu, Sichuan, China
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Not Applicable
Recruiting
- Conditions
- Non-squamous Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2025-09-17
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 440
- Registration Number
- NCT07178795
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BL-M07D1 Versus Investigator's Choice of Chemotherapy in Patients With HER2-positive Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction Adenocarcinoma
Not Applicable
Recruiting
- Conditions
- Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
- Interventions
- Drug: Investigator's choice of chemotherapy
- First Posted Date
- 2025-09-03
- Last Posted Date
- 2025-11-17
- Lead Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Target Recruit Count
- 490
- Registration Number
- NCT07152405
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 20
- Next
News
No news found